Insulet Stock Price, News & Analysis (NASDAQ:PODD)

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) announced its earnings results on Monday, August, 5th. The medical instruments supplier reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by $0.01. The medical instruments supplier earned $177.10 million during the quarter, compared to the consensus estimate of $163.63 million. Insulet had a return on equity of 7.85% and a net margin of 2.66%. Insulet's revenue was up 42.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.03) earnings per share. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Insulet.

Insulet will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet updated its third quarter 2019 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $174-181 million, compared to the consensus revenue estimate of $172.7 million.

14 brokers have issued 1-year target prices for Insulet's stock. Their forecasts range from $100.00 to $185.00. On average, they expect Insulet's share price to reach $144.64 in the next twelve months. This suggests that the stock has a possible downside of 5.7%. View Analyst Price Targets for Insulet.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

Media headlines about PODD stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insulet earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Insulet.

Insulet saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,710,000 shares, an increase of 13.8% from the August 30th total of 4,140,000 shares. Based on an average daily trading volume, of 903,900 shares, the short-interest ratio is presently 5.2 days. Approximately 7.9% of the company's shares are sold short. View Insulet's Current Options Chain.

Some companies that are related to Insulet include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), NuVasive (NUVA), Tandem Diabetes Care (TNDM), ICU Medical (ICUI) and Cantel Medical (CMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), Tandem Diabetes Care (TNDM), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Splunk (SPLK), ServiceNow (NOW), Coupa Software (COUP), EXACT Sciences (EXAS) and salesforce.com (CRM).

Insulet's stock is owned by many different of retail and institutional investors. Top institutional investors include Gradient Investments LLC (0.02%), First Hawaiian Bank (0.01%), Cerebellum GP LLC (0.00%) and Juncture Wealth Strategies LLC (0.00%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was bought by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Cerebellum GP LLC, Juncture Wealth Strategies LLC and Gradient Investments LLC. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $153.39.

Insulet has a market capitalization of $9.24 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

The official website for Insulet is http://www.insulet.com/.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]